Home › NCT07047807

PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Age≥18 years
* Within 8 weeks of a documented decision to pursue neoadjuvant therapy for newly diagnosed, non-metastatic PDAC
* Able to comprehend and speak English

Exclusion Criteria:

* Comorbid health condition that would interfere with study participation, as identified by the cancer care team

About the study

This study aims to refine and pilot test PDAC-PATHWAYS, a digital informational and supportive care app for patients who are initiating neoadjuvant therapy for pancreatic ductal adenocarcinoma (PDAC).

What is being tested

• PDAC-PATHWAYS (behavioral)
• Usual Care (other)

Sponsor: Massachusetts General Hospital · Participants: 50 · Started: Oct 6, 2025

Contact the study team

• Kelsey Lau-Min, MD, MSCE · Phone: 617-724-4000

Official record on ClinicalTrials.gov — NCT07047807

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.